Joseph Stringer

Stock Analyst at Needham

(1.83)
# 1398
Out of 5,383 analysts
345
Total ratings
Success rate
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
320 377
318.07 18.53% 22 Jun 26, 2025
CDTX Cidara Therapeutics
Maintains: Strong Buy
36 54
48.04 12.41% 13 Jun 23, 2025
PHAT Phathom Pharmaceutic...
Maintains: Buy
28 28
9.56 192.89% 52 Jun 6, 2025
VIR Vir Biotechnology
Reiterates: Buy
14 14
5.31 163.65% 18 May 22, 2025
GILD Gilead Sciences
Reiterates: Hold
n/a
n/a n/a 6 May 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
12 12
4 200% 20 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
16 11
2.46 347.15% 19 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
40 29
18.41 57.52% 20 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
66 72
61.42 17.23% 24 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 6 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 55
39.8 38.19% 21 Apr 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
29.9 100.67% 17 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
22 22
11.85 85.65% 22 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
90 90
32.93 173.31% 17 Apr 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 13 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10 10
1.29 675.19% 17 Mar 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 8 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 16 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
37
22.22 66.52% 5 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 5 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 32
n/a n/a 1 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 18
10.74 67.6% 2 Aug 24, 2021